Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 810-821

  Kute, Timothy ^a   Stehle, John R ^a   Ornelles, David ^a   Walker, Natalie ^b   Delbono, Osvaldo ^a   Vaughn, James P ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

ADCC; Breast cancer; Flow cytometry; Trastuzumab; xCELLigence

Indexed keywords

CASPASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANZYME B; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; BLOOD STORAGE; BREAST CANCER; CANCER CELL; CELL ASSAY; CELL SEPARATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOCOMPETENT CELL; MONOCYTE; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84877135653     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20447     Document Type: Article

References (27)

1. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26:60-70; PMID:10482195.
2. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-44; PMID:8622019.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101.
4. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48; PMID:10561337.
5. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010; 116:2856-67; PMID:20564392; http://dx.doi. org/10.1002/cncr.25120.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72; PMID:16236737; http://dx.doi.org/10.1056/NEJMoa052306.
7. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 2011; 11:793-800; PMID:21307659; http://dx.doi.org/10.4161/cbt.11.9.15045.
8. Kute TE, Stehle JR. Development of trastuzumab resistance- Is it only in signaling? In: HER2 and Cancer: Mechanism, Testing and Targeted Theory. Nova Science Publishers, Inc. Hauppauge, NY 2011; 6:161-74.
9. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505- 16; PMID:16829981; http://dx.doi.org/10.1038/nrm1962.
10. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007; 26:3637-43; PMID:17530017; http://dx.doi.org/10.1038/sj.onc.1210379.
11. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10:5650-5; PMID:15355889; http://dx.doi.org/10.1158/1078-0432.CCR-04-0225.
12. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
13. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody- dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94:259-67; PMID:16404427; http://dx.doi.org/10.1038/sj.bjc.6602930.
14. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007; 67:11991-9; PMID:18089830; http://dx.doi.org/10.1158/0008-5472.CAN-07-2068.
15. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26; PMID:11821453; http://dx.doi.org/10.1200/JCO.20.3.719.
16. Mayfield S, Vaughn JP, Kute TE. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res Treat 2001; 70:123-9; PMID:11768602; http://dx.doi.org/10.1023/A:1012999012192.
17. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, et al. Development of Herceptin resistance in breast cancer cells. Cytometry A 2004; 57:86-93; PMID:14750129; http://dx.doi.org/10.1002/cyto.a.10095.
18. Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, Wood J, et al. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother 2009; 58:1887-96; PMID:19340424; http://dx.doi. org/10.1007/s00262-009-0700-0.
19. Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004; 2:363-72; PMID:15357917; http://dx.doi.org/10.1089/adt.2004.2.363.
20. Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, Wang XB, et al. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 2005; 18:154-61; PMID:15720119; http://dx.doi.org/10.1021/tx049721s.
21. Zhu J, Wang X, Xu X, Abassi YA. Dynamic and labelfree monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods 2006; 309:25-33; PMID:16423365; http://dx.doi.org/10.1016/j.jim.2005.10.018.
22. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3:1585-92; PMID:15634652.
23. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2- positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18:23-8; PMID:17159499; http://dx.doi.org/10.1097/01.cad.0000236313.50833.ee.
24. Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007; 6:2065-72; PMID:17620435; http://dx.doi.org/10.1158/1535-7163.MCT-06-0766.
25. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007; 67:11991-9; PMID:18089830; http://dx.doi.org/10.1158/0008-5472.CAN-07-2068.
26. Glamann J, Hansen AJ. Dynamic detection of natural killer cell-mediated cytotoxicity and cell adhesion by electrical impedance measurements. Assay Drug Dev Technol 2006; 4:555-63; PMID:17115926; http://dx.doi.org/10.1089/adt.2006.4.555.
27. Yamada T, Tomita T, Weiss LM, Orlofsky A. Toxoplasma gondii inhibits granzyme B-mediated apoptosis by the inhibition of granzyme B function in host cells. Int J Parasitol 2011; 41:595-607; PMID:21329693; http://dx.doi.org/10.1016/j.ijpara.2010.11.012.